Status:
RECRUITING
Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure
Lead Sponsor:
Jon Simmons
Collaborating Sponsors:
University of South Alabama
Conditions:
Covid19
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This Phase 2 Randomized Placebo Controlled Trial will determine if administering nebulized Dornase Alpha (rhDNase) to COVID-19 patients with respiratory failure is safe and will reduce 28-day mortalit...
Eligibility Criteria
Inclusion
- Male or Female age 18 or older
- On high flow oxygen =/\> 6 liters nasal cannula (or)
- On mechanical ventilation
- Clinical diagnosis of COVID-19 \& positive PCR test (or)
- Clinical diagnosis of COVID-19 \& negative PCR test with clinical symptoms of COVID-19 and pathognomonic lesions on a chest CT scan
Exclusion
- Known allergy to Pulmozyme
- Less than 18 years of age
- Grave condition with anticipated death within 48 hours; at the discretion of treating physician.
- Enrollment in another clinical trial receiving investigatory drugs
Key Trial Info
Start Date :
April 28 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 28 2022
Estimated Enrollment :
44 Patients enrolled
Trial Details
Trial ID
NCT04445285
Start Date
April 28 2020
End Date
February 28 2022
Last Update
May 28 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of South Alabama
Mobile, Alabama, United States, 36617